In the UK, like on a global level, personalized oncology healthcare approaches have seen a dramatic increase. This would suggest a positive development for patients in the UK, but it also entails some potential huge difficulties for the NHS. Data suggests that half of biopharma are integrating personalized medicine into their product development to help with product differentiation and therefore market access. Local commissioning groups in the UK have to manage the budget impact of oncology products, with the advances in cancer treatment outstripping the available financial resources. Although measures have been introduced to support patient access to advancing cancer treatments in the UK, the current variation in access is undermining public confidence in the NHS.
This webinar sponsored by Quintiles, will bring together experts from key oncology viewpoints, a market access expert from Quintiles and a consultant clinical oncologist to provide valuable insight on this important biopharma debate.
Key Learning Objectives:
Who Should Attend:
Decision makers in Market Access, Regulatory Affairs, Real-World / Late Phase research, HEOR, patient-centric / patient engagement programs, payer / provider relations, Brand managers, Marketing Managers/Directors, Pricing & Reimbursement, Medial Affairs, Executive Management, Health Technology Assessment, Pharmacovigilance
Dean Summerfield, DPhil
Senior Vice President, Commercial and Consulting
Dr Jason Lester
Consultant Clinical Oncologist
Velindre Cancer Centre